Artykuły w czasopismach na temat „Cancer treatment”
Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Cancer treatment.
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Cancer treatment”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
1
Shukla, Dr Rajesh, i Dr Sanjay Shukla. "Radiosurgery an Emerging Treatment Option in Cancer Treatment and Non Cancer Condition". Indian Journal of Applied Research 3, nr 12 (1.10.2011): 407–9. http://dx.doi.org/10.15373/2249555x/dec2013/124.
Pełny tekst źródła
2
A, Santhiya Grace, Devi Kala Rathinam D i Sherin J. "Nanorobots in Cancer Treatment". International Journal of Trend in Scientific Research and Development Volume-2, Issue-5 (31.08.2018): 117–20. http://dx.doi.org/10.31142/ijtsrd15782.
Pełny tekst źródła
3
Shahab, Ariba, i Subuhi Anwar. "CRUCUMIN ROLE IN BREAST CANCER TREATMENT". Era's Journal of Medical Research 10, nr 01 (czerwiec 2023): 97–103. http://dx.doi.org/10.24041/ejmr2023.16.
Pełny tekst źródłaStreszczenie:
One of the most common forms of malignant tumors is breast cancer worldwide, has a high fatality rate. The development of novel chemicals and technological advancements that will allow the adoption of safer and more efficient therapeutic techniques has received a lot of attention in order to address this problem. In order to maximize tumor growth inhibition and reduce side effects, it has been suggested that combining nanoparticles with well-known anticancer agents including compounds derived from plants, like curcumin is an effective strategy. Curcumin exploits a complex network of molecular signals, including the proliferative, ER, and HER2 pathways, to exert its anticancer actions. According to experimental results, curcumin controls genes associated to cell phase, microRNA, and apoptosis in breast cancer cells.
4
Souchelnytskyi, S. "INDIVIDUALIZATION OF CANCER TREATMENT: CONTRIBUTION OF OMICS TECHNOLOGIES TO CANCER DIAGNOSTIC". Biotechnologia Acta 6, nr 4 (2013): 105–17. http://dx.doi.org/10.15407/biotech6.04.105.
Pełny tekst źródła
5
ML, Choudhary. "A Review on Cancer, Cause of Cancer and Treatment: Role of PIK3 Pathway on Cancer". Bioequivalence & Bioavailability International Journal 7, nr 2 (4.07.2023): 1–17. http://dx.doi.org/10.23880/beba-16000208.
Pełny tekst źródłaStreszczenie:
The central function of phosphoinositide 3- kinase (PI3K) activation in tumour cell biology has urged a sizeable trouble to target PI3K and/ or downstream kinases similar as AKT and mammalian target of rapamycin (mTOR) in cancer. still, arising clinical data show limited single- agent exertion of impediments targeting PI3K, AKT or mTOR at permitted boluses. One exception is the response to PI3Kδ impediments in habitual lymphocytic leukaemia, where a combination of cell- natural and- foreign conditioning drive efficacity. Then, we review crucial challenges and openings for the clinical development of impediments targeting the PI3K – AKT – mTOR pathway. Through a lesser focus on patient selection, increased understanding of vulnerable modulation and strategic operation of rational combinations, it should be possible to realize the eventuality of this promising class of targeted anticancer agents.
6
Vsevolod, Dolhyi, Avierin Dmytro i Hojouj Mohammad. "Tubulin Role in Cancer Development and Treatment". Cancer Medicine Journal 2, nr 2 (31.12.2019): 45–54. http://dx.doi.org/10.46619/cmj.2019.2-1013.
Pełny tekst źródłaStreszczenie:
This review work is done to show a significance of tubulin in cancer development. Within last decades there are a lot of studies have performed in this area. Now it is clear that there are an enormous number of functions in cell performing by microtubules, a structure unit of which is tubulin. Now it used widely as a predictive factor of tumor aggressiveness, but increasingly it becomes a target for studying and treatment elaboration, since it is well-known that to now a day's tubulin-targeted medicines, such as taxanes or vinca-alkaloids, resistance develops rather quickly, so it consists a large problem in oncology. This work reveals basic microtubule functions, violations that it may undergo and consequences of these. Also it is described here the main modern tendencies in creation of remedy which will make it possible breakthrough treatment resistance barrier.
7
Ndukwe, Munachiso Onyedikachi, Ivan Práznovec, Martin Štěpán, Igor Sirák, Aleš Fibír i Jiří Špaček. "Treatment options for locally recurrent vulvar cancer". Česká gynekologie 86, nr 4 (30.08.2021): 246–48. http://dx.doi.org/10.48095/cccg2021246.
Pełny tekst źródłaStreszczenie:
Summary: Objective: Summarizing of treatment options for locally recurrent vulvar cancer in patients after previous complex oncological treatment and presenting a case report from our department. Methods: Presenting a case report of a patient after previous complex oncological treatment for spinocellular cancer of the vulva who presented with a locally recurrent tumor. The patient was treated with a wide radical local excision of the tumor followed by a posterior thigh fl ap graft. Conclusion: Surgical intervention is the primary mode of treatment in locally recurrent cancers of the vulva. Wide radical local excision as a mode of treatment can be optimized by the use of grafts aiding in wound healing.
8
Greschuchna, D. "Surgical Treatment of Small Cell Lung Cancer". Journal of the Japanese Association for Chest Surgery 3, nr 2 (1989): 169. http://dx.doi.org/10.2995/jacsurg1987.3.2_169.
Pełny tekst źródła
9
OPRISAN, Emilia, i Mirela ZIVARI. "Psychological Implications of Cancer Treatment in Pregnancy". Revista Romaneasca pentru Educatie Multidimensionala 06, nr 02 (30.12.2014): 29–38. http://dx.doi.org/10.18662/rrem/2014.0602.03.
Pełny tekst źródła
10
Tyagi, Nidhi, Ganesh N. Sharma, Birendra Shrivastava, Prasoon Saxena i Nitin Kumar. "Medicinal plants: used in Anti-cancer treatment". International Journal of Research and Development in Pharmacy & Life Sciences 6, nr 5 (sierpień 2017): 2732–39. http://dx.doi.org/10.21276/ijrdpl.2278-0238.2017.6(5).2732-2739.
Pełny tekst źródła
11
P, Balaganesan. "Mathematical Analysis of Virotherapy Treatment for Cancer". Chettinad Health City Medical Journal 12, nr 04 (30.12.2023): 81–86. http://dx.doi.org/10.24321/2278.2044.202376.
Pełny tekst źródła
12
Ruckenstuhl, Paul, Michael Schippinger, Paul Liebmann, Andreas Leithner i Gerwin Bernhardt. "Like or Dislike? Impact of Facebook on Ewing Sarcoma Treatment". JMIR Cancer 2, nr 2 (25.08.2016): e11. http://dx.doi.org/10.2196/cancer.5367.
Pełny tekst źródła
13
Barley, Victor. "Cancer treatment and causation". Clinical Risk 13, nr 4 (1.07.2007): 151–53. http://dx.doi.org/10.1258/135626207781251068.
Pełny tekst źródłaStreszczenie:
A series of three articles exploring medicolegal issues arising out of the detection and treatment of cancer. The treatment of cancer involves several different specialists and, in the majority of cancer services in the UK, patients with cancer are seen by a multidisciplinary team. After the diagnosis of cancer has been confirmed by histological examination which shows the type and grade of the cancer, further tests are usually needed to determine the extent and spread of the tumour, i.e. the stage. Many cancers have already spread before the diagnosis can be made, even if the metastases cannot be detected at the time of the initial diagnosis. Many cancers are therefore not curable even though there is no indication of spread from the initial tests. Therefore, an unwarranted delay in diagnosis may not result in a poorer prognosis, although it is clearly important to give treatment at the earliest opportunity to reduce the possibility of spread. This article outlines the basic knowledge required by a clinical negligence practitioner when considering a potential oncology claim.
14
Corbett, Teresa, Jane C. Walsh, AnnMarie Groarke, Rona Moss-Morris, Eimear Morrissey i Brian E. McGuire. "Cancer-Related Fatigue in Post-Treatment Cancer Survivors: Theory-Based Development of a Web-Based Intervention". JMIR Cancer 3, nr 2 (4.07.2017): e8. http://dx.doi.org/10.2196/cancer.6987.
Pełny tekst źródła
15
Bashir, Azeem, Saloni Verma, Simrat Kaur i S. P. Subashini. "Breast Cancer and Its Conventional Treatment: A Preliminary Review". Indian Journal of Genetics and Molecular Research 11, nr 1 (15.06.2022): 21–25. http://dx.doi.org/10.21088/ijgmr.2319.4782.11122.2.
Pełny tekst źródłaStreszczenie:
Worldwide, breast cancer is the maximum common cancer in ladies and might be the leading cause of most cancers in women. Better-paid nations (HICs) have made terrific strides in enhancing the consequences of breast cancer. Between 1990 and 2014, the mortality price of breast cancers dropped by means of 34 percent due to the combination of superior pre-diagnosis and powerful adjuvant remedies. In evaluation, breast cancer is developing trouble in low- and center-earnings nations (LMICs), where the low prevalence price has risen to 5% according to year. The measures identified within the HICs had been no longer established in LMICs wherein complete control techniques from wealthy countries couldn't be fully utilized because of critical resource constraints associated with constrained personal sources, underdeveloped fitness care infrastructure, drug shortages and cultural obstacles.
16
Ayman, Rasmy, Ameen Amal i AbdMonem Amira. "Lung Cancer Treatment: Incidence and Survival: SEER Database". Cancer Medicine Journal 2, nr 2 (31.12.2019): 36–40. http://dx.doi.org/10.46619/cmj.2019.2-1011.
Pełny tekst źródłaStreszczenie:
Lung cancer is the most common cause of cancer death worldwide, with an estimated 1.6 million deaths each year. Nearly 85% of cases have a different histological groups jointly recognized as “Non-Small Cell Lung Cancer of which lung adenocarcinoma and lung squamous cell carcinoma are the most common subtypes”.
17
Morales, Alvaro, Marc Riviere i Nigel Phillips. "Developments in the Treatment of Superficial Bladder Cancer". Japanese Journal of Urology 96, nr 2 (2005): 42. http://dx.doi.org/10.5980/jpnjurol.96.42_2.
Pełny tekst źródła
18
Scardino, Peter T. "IL3 Surgical Treatment for Localized Prostate Cancer(IL)". Japanese Journal of Urology 97, nr 2 (2006): 86. http://dx.doi.org/10.5980/jpnjurol.97.86.
Pełny tekst źródła
19
Srivastava, Anand Narain, Jata Shankar Misra, Sharique Ahmad i Subuhi Anwar. "ORAL CANCER: NOVEL TREATMENTS AND APPROACHES". Era's Journal of Medical Research 9, nr 2 (grudzień 2022): 256–61. http://dx.doi.org/10.24041/ejmr2022.40.
Pełny tekst źródłaStreszczenie:
The aggressive tumour known as oral cancer can metastasize, produce a high fatality rate, and infect nearby tissue. Surgery, chemotherapy, and radiation therapy, for example, are common treatment options that, when used in clinical settings, have both minimal drawbacks and major side effects. Currently, oral therapeutic medication delivery using targeted drug administration is proving to be effective. In recent years, an effective alternative therapy known as “nanomedicine,” or using nanoplatforms to deliver drugs for the treatment of cancer, has evolved. Thanks to the use of nanoplatforms, drug delivery to the tumour site can be done precisely and with minimal drug degradation in the body. As a result, the drug's toxicity is diminished, its concentration at the tumour site is elevated, and its distribution to other organs is kept to minimum. We present a contemporary review of the development medication delivery targeted for the treatment of oral cancer in this article different oral delivery systems, including as cyclodextrins, liposomes, hydrogel-based forms, and nanolipids are highlighted and explored. Biomimetic systems, such as therapeutic vitamins, proteins, exosomes, and virus-like particles, with a focus on cancer treatment, are also described. The study concludes with a brief analysis of future applications for nanoplatforms in the treatment of oral cancer.
20
Mensah-Osman, Edith J. "Insomnia in cancer patients." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): e18657-e18657. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18657.
Pełny tekst źródłaStreszczenie:
e18657 Background: As new treatments extend patient survival, the quality of their lives (QoL) grows in importance. QoL may differentiate alternative treatments, and QoL assessment has become a standard component of treatment evaluations. Sleep is a key component of QoL. Insomnia can worsen pain, fatigue, depression and cognitive impairments in cancer patients. Inappropriate treatments for insomnia can further worsen these and interact with chemotherapy medications. Recognizing this, in 2019 the American Society of Clinical Oncology identified Insomnia as a key patient-reported outcome performance measure (PRO-PM) for the National Quality Forum to consider. Methods: Through review of the scientific literature the project identified specific cancers and their treatments where treating Insomnia can have a significant impact on patient QoL. PubMed, Pharmapendium, and Science Direct databases were used. Search terms included “insomnia demographics, epidemiology of insomnia in cancer, insomnia in tumor types, cancer insomnia, insomnia associated hormonal treatment, insomnia in patients awaiting cancer diagnosis; insomnia in cancer care-givers, insomnia in cancer survivors, cancers treated with corticosteriods”. Original research articles in English that used human subjects between January 1, 1993 and January 31, 2020 were included. Results: Insomnia is associated with specific tumor types: brain tumors, breast cancer, gastrointestinal cancer, leukemia, lymphoma, multiple myelomaand terminal cancer. Autoimmune causes of insomnia in paraneoplastic syndromes. Insomnia is prevalent in oncology patients being evaluated, awaiting diagnosis and treatment. Age and gender are demographic factors associated with oncology insomnia. Insomnia is associated with specific antineoplastic agents. Corticosteroid use is associated with insomnia, before, during and after cancer treatment. Insomnia in cancer survivors starts during their treatment and may persist for years. Conclusions: Specific demographics, cancers and treatments are associated with insomnia. Insomnia often occurs in patients undergoing evaluations for cancer. Insomnia is often not recognized and not treated in oncology patients. Insomnia that is not addressed during cancer treatment often persists in cancer survivors. There is the need to investigate whether treating insomnia early in cancer patients during their course of treatment can reduce symptoms such as fatigue and improve their QOL.
21
Mensah-Osman, Edith J. "Insomnia in cancer patients." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): e18657-e18657. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18657.
Pełny tekst źródłaStreszczenie:
e18657 Background: As new treatments extend patient survival, the quality of their lives (QoL) grows in importance. QoL may differentiate alternative treatments, and QoL assessment has become a standard component of treatment evaluations. Sleep is a key component of QoL. Insomnia can worsen pain, fatigue, depression and cognitive impairments in cancer patients. Inappropriate treatments for insomnia can further worsen these and interact with chemotherapy medications. Recognizing this, in 2019 the American Society of Clinical Oncology identified Insomnia as a key patient-reported outcome performance measure (PRO-PM) for the National Quality Forum to consider. Methods: Through review of the scientific literature the project identified specific cancers and their treatments where treating Insomnia can have a significant impact on patient QoL. PubMed, Pharmapendium, and Science Direct databases were used. Search terms included “insomnia demographics, epidemiology of insomnia in cancer, insomnia in tumor types, cancer insomnia, insomnia associated hormonal treatment, insomnia in patients awaiting cancer diagnosis; insomnia in cancer care-givers, insomnia in cancer survivors, cancers treated with corticosteriods”. Original research articles in English that used human subjects between January 1, 1993 and January 31, 2020 were included. Results: Insomnia is associated with specific tumor types: brain tumors, breast cancer, gastrointestinal cancer, leukemia, lymphoma, multiple myelomaand terminal cancer. Autoimmune causes of insomnia in paraneoplastic syndromes. Insomnia is prevalent in oncology patients being evaluated, awaiting diagnosis and treatment. Age and gender are demographic factors associated with oncology insomnia. Insomnia is associated with specific antineoplastic agents. Corticosteroid use is associated with insomnia, before, during and after cancer treatment. Insomnia in cancer survivors starts during their treatment and may persist for years. Conclusions: Specific demographics, cancers and treatments are associated with insomnia. Insomnia often occurs in patients undergoing evaluations for cancer. Insomnia is often not recognized and not treated in oncology patients. Insomnia that is not addressed during cancer treatment often persists in cancer survivors. There is the need to investigate whether treating insomnia early in cancer patients during their course of treatment can reduce symptoms such as fatigue and improve their QOL.
22
PATEL, PRABHUDAS, HEMANGINI VORA, BHARAT B. AGGARWAL, VARSHA GANDHI, KAPIL MEHTA i SEN PATHAK. "Prevention and Treatment of Cancer: Hypes and Hopes 6th International Translational Cancer Research Conference". Anticancer Research 36, nr 9 (9.09.2016): 4971–76. http://dx.doi.org/10.21873/anticanres.11066.
Pełny tekst źródła
23
Ghadyalpatil, Nikhil Suresh, Chopra Supriya, Patil Prachi, Dsouza Ashwin i Saklani Avanish. "Gastrointestinal cancers in India: Treatment perspective". South Asian Journal of Cancer 05, nr 03 (lipiec 2016): 126–36. http://dx.doi.org/10.4103/2278-330x.187585.
Pełny tekst źródłaStreszczenie:
AbstractGI cancer is not one cancer but is a term for the group of cancers that affect the digestive system including gastric cancer (GC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), esophageal cancer (EC), and pancreatic cancer (PC). Overall, the GI cancers are responsible for more cancers and more deaths from cancer than any other organ. 5 year survival of these cancers remains low compared to western world. Unlike the rest of the world where organ based specialities hepatobiliary, pancreatic, colorectal and esophagogastric exist , these cancers are managed in India by either a gastrointestinal surgeons, surgical oncologist, or a general surgeon with varying outcomes.The aim of this review was to collate data on GI cancers in indian continent. In colorectal cancers, data from tertiary care centres identifies the unique problem of mucinous and signet colorectal cancer. Results of rectal cancer resection in terms of technique (intersphincteric resection, extralevator aper, minimal invasive approach ) to be comparable with world literature. However long term outcome and data regarding colon cancers and nationally is needed. Gastric cancer at presentation are advanced and in surgically resected patients, there is need for a trial to compare chemoradiation vs chemotherapy alone to prevent loco regional recurrence. Data on minimal invasive gastric cancer surgery may be sparse for the same reason. Theree is a lot of data on surgical techniques and perioperatve outcomes in pancreatic cancer. There is a high volume of locally advanced gallbladder cancers with efforts on to decide whether neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy is better for down staging. Considering GI cancers, a heterogeneous disease with site specific treatment options and variable outcomes, the overall data and outcomes are extremely variable. Young patients with pathology unique to the Indian subcontinent (for example, signet ring rectal cancer, GBCs) need focussed attention. Solution for such pathology needs to come from the Indian continent itself. Joint efforts to improve outcomes for GI cancer can be integrated under the national cancer grid program.
24
Muhandiramge, Jaidyn, Erica T. Warner, John R. Zalcberg, Andrew Haydon, Galina Polekhina, Gijsberta J. van Londen, Peter Gibbs i in. "Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS)". Cancers 15, nr 4 (5.02.2023): 1017. http://dx.doi.org/10.3390/cancers15041017.
Pełny tekst źródłaStreszczenie:
Introduction: Cancer treatment planning in older adults is complex and requires careful balancing of survival, quality of life benefits, and risk of treatment-related morbidity and toxicity. As a result, treatment selection in this cohort tends to differ from that for younger patients. However, there are very few studies describing cancer treatment patterns in older cohorts. Methods: We used data from the ASPirin in Reducing Events in the Elderly (ASPREE) trial and the ASPREE Cancer Treatment Substudy (ACTS) to describe cancer treatment patterns in older adults. We used a multivariate logistic regression model to identify factors affecting receipt of treatment. Results: Of 1893 eligible Australian and United States (US) participants with incident cancer, 1569 (81%) received some form of cancer treatment. Non-metastatic breast cancers most frequently received treatment (98%), while haematological malignancy received the lowest rates of treatment (60%). Factors associated with not receiving treatment were older age (OR 0.94, 95% CI 0.91–0.96), residence in the US (OR 0.34, 95% CI 0.22–0.54), smoking (OR 0.57, 95% CI 0.40–0.81), and diabetes (OR 0.56, 95% CI 0.39–0.80). After adjustment for treatment patterns in sex-specific cancers, sex did not impact receipt of treatment. Conclusions: This study is one of the first describing cancer treatment patterns and factors affecting receipt of treatment across common cancer types in older adults. We found that most older adults with cancer received some form of cancer treatment, typically surgery or systemic therapy, although this varied by factors such as cancer type, age, sex, and country of residence.
25
Akanksha, Akanksha, Vandana Vandana, Komal Kaushik, Gunjan Choudhary, Runjhun Mathur i Abhimanyu Kumar Jha. "Possible Treatment of Liver Cancer using Natural Compounds-Review". SSR Institute of International Journal of Life Sciences 7, nr 4 (lipiec 2021): 2827–33. http://dx.doi.org/10.21276/ssr-iijls.2021.7.4.1.
Pełny tekst źródła
26
Shahabaz, Amir, i Muhammad Afzal. "Implementation of High Dose Rate Brachytherapy in Cancer Treatment". Science Progress and Research 1, nr 3 (11.06.2021): 77–106. http://dx.doi.org/10.52152/spr/2021.121.
Pełny tekst źródłaStreszczenie:
A technique of radiation therapy delivery in which the radioactive sources are placed very close or even inside the target volume is called Brachytherapy (BT). Brachytherapy is a type of radiation therapy. It destroys cancer cells by making it hard for them to multiply. In this technique, a radiation source is placed directly into or near a tumour. High dose-rate brachytherapy is also known as HDR brachytherapy, or temporary brachytherapy. It is a type of internal radiotherapy. HDR was developed to reduce the risk of cancer recurrence while shortening the amount of time it takes to get radiation treatment. HDR also limits the dose of radiation (associated side effects) to surrounding normal tissue. The important benefits of HDR brachytherapy include extremely precise radiation therapy delivered internally, used alone or after surgery to help prevent cancer recurrence, convenient treatments that are usually pain-free, and a reduction in the risk of common short- and long-term side effects. Currently, tumour dose, as well as doses of the surrounding normal structures, can be evaluated accurately, and high-dose-rate brachytherapy enables three-dimensional image guidance. The biological disadvantages of high-dose-rate were overcome by fractional irradiation. In the definitive radiation therapy of cervical cancer, high-dose-rate brachytherapy is most necessary. Most patients feel little discomfort during brachytherapy. There is no residual radioactivity when the treatment is completed. A patient may be able to go home shortly after the procedure, resuming his normal activities with few restrictions. An advantage of brachytherapy is to deliver a high dose to the tumour during treatment and save the surrounding normal tissues. High-dose-rate (HDR) brachytherapy has great promise with respect to proper case selection and delivery technique because it eliminates radiation exposure, can be performed on an outpatient basis and allows short treatment times. Additionally, by varying the dwell time at each dwell position, the use of a single-stepping source allows optimization of dose distribution. As the short treatment times do not allow any time for correction of errors, and mistakes can result in harm to patients, so the treatments must be executed carefully by using HDR brachytherapy. Refinements will occur primarily in the integration of imaging (computed tomography, magnetic resonance imaging, intraoperative ultrasonography) and optimization of dose distribution and it is expected that the use of HDR brachytherapy will greatly expand over the next decade. Various factors in the development of well-controlled randomized trials addressing issues of efficacy, quality of life, toxicity and costs-versus-benefits will ultimately define the role of HDR brachytherapy in the therapeutic armamentarium. Surrounding healthy tissues are not affected by the radiation due to the ability to target radiation therapy at high dose rates directly to the tumour. Treatment to be delivered as an outpatient in as few as one to five sessions is also allowed by this targeted high dose approach. HDR brachytherapy is the most precision radiation therapy, even better than carbon ion therapy. At the time of invasive placement of the radiation source into the tumour area, brachytherapy requires the skills and techniques of radiation oncologists.
27
LU, Vinicius. "Evaluation of Cancer Treatment by using DOXORUBICIN HYDROCHLORIDE LIPOSOMES". Cancer Research and Cellular Therapeutics 2, nr 2 (1.08.2018): 01–03. http://dx.doi.org/10.31579/2640-1053/028.
Pełny tekst źródłaStreszczenie:
The goal of any drug delivery system is to provide a therapeutic amount of drug to the proper site in the body, to achieve promptly and then maintain the desired drug concentration. Conventional drug delivery system achieves as well as maintains the drug concentration with in the therapeutically effective range needed for treatment only when taken several times a day. This results in a significant fluctuation in drug level (Chien YM., 1992). The concept of designing specified delivery system to achieve selective drug targeting has been originated from the perception of Paul Ehrlich, who proposed drug delivery to be as a “magic bullet”.Controlled & Novel delivery envisages optimized drug in the sense that the therapeutic efficacy of a drug is optimized, which also implies nil or minimum side effects. It is expected that the 21st century would witness great changes in the area of drug delivery. The products may be more potent as well as safer. Target specific dosage delivery is likely to overcome much of the criticism of conventional dosage forms.
28
A, Kumar. "Tumour Metabolism: An Emerging Therapeutic Target for Cancer Treatment". International Journal of Zoology and Animal Biology 2, nr 3 (2019): 1–2. http://dx.doi.org/10.23880/izab-16000156.
Pełny tekst źródła
29
ÖZCAN, Öznur Özge. "CANCER DIAGNOSTICS, IMAGING AND TREATMENT BY NANOSCALE STRUCTURES TARGETING". Biotechnologia Acta 12, nr 6 (grudzień 2019): 12–24. http://dx.doi.org/10.15407/biotech12.06.012.
Pełny tekst źródła
30
Bachhav, Rushikesh. "Innovative Treatment Strategy for Cancer with Nanotechnology: A Review". Nanomedicine & Nanotechnology Open Access 9, nr 1 (2024): 1–10. http://dx.doi.org/10.23880/nnoa-16000283.
Pełny tekst źródłaStreszczenie:
By reducing collateral toxicity to nonmalignant cells, nanotechnology has the potential to improve the efficacy and selectivity of chemical, physical, and biological methods for inducing cancer cell death. More and more materials at the nanoscale are being actively and passively targeted to specifically target cancer cells. This review focuses on how different tactics with distinct identifying qualities set nanoparticles apart from earlier anticancer medicines in terms of their capacity to recognize cells. Additionally, it talks about how precise medication delivery via nanoparticles inside the cells has been the subject of numerous successful studies, as well as how nanoparticles can be used to treat cancer specifically while removing the side effects of conventional medicines.
31
Antonio Cacho Orea, Marco, Hilberth Christian Lopez Masters, Diaz Barrientos Cheryl Zilahy i Maria Jose Mendoza Ramirez. "Second - Level Surgical Treatment of Splenic Angle Colon Cancer". International Journal of Science and Research (IJSR) 13, nr 5 (5.05.2024): 1370–71. http://dx.doi.org/10.21275/sr24521013150.
Pełny tekst źródła
32
A, Panja. "Plant Secondary Metabolites in Cancer Treatment: A Mini Review". Open Access Journal of Microbiology & Biotechnology 9, nr 2 (2.04.2024): 1–4. http://dx.doi.org/10.23880/oajmb-16000291.
Pełny tekst źródłaStreszczenie:
Plant-based medicines have been utilized since ancient times to treat a variety of human and animal illnesses one such disease is cancer. Cancer is a multistage process that involves the uncontrolled and sudden division of cells and is one of the primary causes of death. Over the past few years, plant secondary metabolites have gained substantial attention for their potential role in cancer treatment and cure. These metabolites, due to their diverse chemical structures and biological activities have shown to have potential in the treatment of cancer with minimal side effects. These bioactive compounds are produced by plants as a defense mechanism against herbivores and pathogens, and they have been found to exhibit anti-cancer properties in vitro and in vivo. They demonstrate their anticancer activities by eliminating free radicals, triggering apoptosis, and blocking angiogenesis in cancer cells. Over the years, a number of plant-derived compounds have demonstrated potential anticancer effects in vitro and in vivo. This mini-review seeks to offer an overview of current research on plant secondary metabolites and their potential use in cancer therapy. The review discusses the many types of plant secondary metabolites that have been studied for their anti-cancer activities, such as alkaloids, flavonoids, terpenoids, and phenols. The review also examines these metabolite's methods of action, which include apoptosis induction, cell cycle arrest, and angiogenesis suppression. Overall, plant secondary metabolites hold considerable promise as a source of new anti-cancer drugs, but more study is needed to fully realize their potential.
33
Long, R., J. Luzuriaga, C. Biondi, A. Woods, P. Jackson, C. Anderiesz, C. Giles i H. Zorbas. "Collection and Reporting of System-Wide Cancer Treatment Activity Data As Part of the Stage, Treatment and Recurrence (STaR) Project". Journal of Global Oncology 4, Supplement 2 (1.10.2018): 74s. http://dx.doi.org/10.1200/jgo.18.61400.
Pełny tekst źródłaStreszczenie:
Background: The need for high quality, comprehensive national data on the treatments applied to cancers is widely recognized within the Australian cancer control community. The analysis and reporting of cancer treatment data will greatly enhance our ability to better understand cancer care activity and outcomes - and in particular the treatments being applied across population groups. Aim: To collect and report national data on cancer treatments, as part of Cancer Australia's Stage, Treatment and Recurrence (STaR) project. The linking of this data with national data on stage at diagnosis, survival and recurrence, will help inform policy and practice and ultimately improve cancer outcomes. Methods: Cancer Australia developed a dataset of selected surgical procedures for the treatment of the top five incidence cancers (prostate, breast, colorectal, lung, and melanoma). A dataset of key selected radiotherapy, and systemic therapies for the treatment of all cancer types was also developed. Data for reporting system-wide treatment activity were extracted from existing national health administrative datasets, including: the Pharmaceutical Benefits Scheme (PBS), the Medicare Benefits Schedule (MBS) and the National Hospital Morbidity Database (NHMD). The scope of the analysis was selected surgical procedures, radiotherapy procedures, or pharmaceutical agents administered with the general intent to change the outcome of the cancer and/or provide symptom relief/ palliative care. Results: The data reported provide a high-level national system-wide overview of cancer treatments applied, including: • More than 1 million radiotherapy services were provided for all cancers combined in Australia (as indicated by MBS reimbursement claims data) for the years 2013 to 2015 inclusive; • The number of people receiving systemic anticancer therapies in Australia for all cancers combined (as indicated by PBS reimbursement claims data) increased from 198,756 in 2012 to 247,939 in 2016; and • The number of hospital separations recorded in the NHMD (i.e., episodes of admitted patient care) for patients with a principal diagnosis of cancer undergoing surgery for the treatment of the top five high incidence cancers in Australia increased from 53,516 in 2010 to 57,651 in 2015. Conclusion: National cancer treatment data were successfully collected and reported. Australia is one of very few countries in the world to collect and report national system-wide treatment data with a specific focus on cancer. These data will be linked to cancer incidence, stage at diagnosis, survival and recurrence data to help inform for population-level reporting of cancer outcomes.
34
Lee, Suee. "Hormone Treatment for Breast Cancer". Korean Journal of Medicine 98, nr 6 (1.12.2023): 283–88. http://dx.doi.org/10.3904/kjm.2023.98.6.283.
Pełny tekst źródłaStreszczenie:
Hormone receptor-positive breast cancer accounts for 60-70% of all breast cancers and has a better prognosis than human epidermal growth factor receptor-2 (HER2)-positive or triple-negative breast cancer. Hormone treatment for breast cancer is an important treatment method that is effective and has few side effects for hormone receptor-positive breast cancer. Hormone therapy is performed as adjuvant therapy in early breast cancer and as palliative therapy in metastatic breast cancer. In the past decade, molecularly targeted agents against intracellular targets such as mammalian target of rapamycin (everolimus), cyclin-dependent kinase 4 and 6 (palbociclib, ribociclib, abemaciclib), and phosphatidylinositol 3-kinase (alpelisib) has offered patients effective therapeutic options, and combination of hormone treatment with the molecular agents have continued to improve the outcome of breast cancer.
35
Krasnoselskyi, M. V., V. I. Starikov i A. S. Khodak. "Topical issues of esophageal cancer and gastroesophageal cancer surgery". Український радіологічний та онкологічний журнал 28, nr 2 (25.06.2020): 118–32. http://dx.doi.org/10.46879/ukroj.2.2020.118-132.
Pełny tekst źródłaStreszczenie:
Background. Esophageal cancer (MS) ranks 14th in the structure of cancer in the population of Ukraine. Gastroesophageal cancer (GER) is several times more common. It is estimated that cancer in this area accounts for more than 20 % of all stomach cancers. The results of cancer treatment in this location are the worst among other cancers. This is due to high neglect in newly diagnosed patients, high postoperative mortality (15 %) and low five-year survival.
Purpose. To analyze the literature sources related to esophageal cancer and gastroesophageal cancer surgery development in chronological terms and to define the main directions for further development of surgery of this pathology.
Materials and methods. The literature review has involved available full-text contributions obtained via literature search in domestic and foreign databases. The search was restricted to the studies published within the 1975–2020 timeframe.
Special emphasis was placed on the effectiveness analysis of lymph node dissection and methods of esophagogastric anastomosis forming, in a comparative aspect. The paper also analyzes the materials of the authors’ own long-term studies related to this issue. From 1990 to 2018, 250 patients with esophageal cancer and gastroesophageal cancer were treated at SO «IMR of the NAMS of Ukraine» and the regional clinical oncology dispensary.
Results and discussion. Literature suggests that the failure of the esophageal-gastric anastomosis is secondary among complications. Cardiovascular and pulmonary complications come first.
When performing 3-zone lymph dissection increases five-year survival by 10 %. The inability of the esophagogastric anastomosis in leading clinics is from 3 to 9 %. Performing a plastic esophagogastric anastomosis increases its physiological properties.
Conclusions. Thus, surgical treatment remains the main strategic direction in the treatment of MS and GER. The primary goal of treatment is the survival of patients.
Data from literature sources indicate the need for mandatory mediastinal and abdominal lymph dissection. The most successful results of treatment of esophageal cancer and gastroesophageal cancer were obtained in leading specialized oncology clinics where the lowest postoperative mortality is observed. Treatment of cancer in this location requires the use of adjuvant treatments (chemotherapy and radiation therapy).
36
Young-Afat, Danny A., Carla H. van Gils, David J. Bruinvels, Carmen C. van der Pol, Arjen J. Witkamp, Sieta Sijtsema, Yvette Jonasse i in. "Patients’ and Health Care Providers’ Opinions on a Supportive Health App During Breast Cancer Treatment: A Qualitative Evaluation". JMIR Cancer 2, nr 1 (7.06.2016): e8. http://dx.doi.org/10.2196/cancer.5334.
Pełny tekst źródła
37
Shuja, Naveed. "Nanotechnology: Revolutionizing Cancer Diagnosis and Treatment". DEVELOPMENTAL MEDICO-LIFE-SCIENCES 1, nr 1 (6.07.2024): 1. http://dx.doi.org/10.69750/dmls.01.01.032.
Pełny tekst źródłaStreszczenie:
Nanotechnology: Revolutionizing Cancer Diagnosis and Treatment The creation of nanotechnology marks a pivotal transformation within the landscape of cancer diagnosis and treatment. As we stand getting ready to this technological revolution, the potential of nanotechnology to significantly beautify the precision, efficiency, and effectiveness of most cancers care is becoming increasingly evident[1]. This editorial explores the profound impact nanotechnology is having on most cancers analysis and treatment, highlighting key improvements and their implications for the future of oncology[2]. The Promise of Nanotechnology in Cancer Care Nanotechnology, the science of manipulating materials at the atomic and molecular scale, has opened new frontiers in medication, particularly in oncology. Its capacity to interact with organic structures at the mobile and molecular degrees lets in for unparalleled precision in diagnosing and treating most cancers. Nano-enzymes, nanoparticles, and nanocarriers are most of the modern tools being advanced and deployed to combat cancer more correctly. Enhancing Cancer Diagnosis Traditional most cancers diagnostic methods frequently be afflicted by obstacles in sensitivity and specificity, leading to delayed detection and suboptimal remedy outcomes. Nanotechnology addresses these demanding situations via allowing the development of relatively touchy diagnostic gear that could detect cancer at its earliest stages. For example, nanoparticles may be engineered to target particular cancer biomarkers, imparting extra correct and early detection as compared to traditional imaging strategies[3, 4]. Biosensors incorporating nanoparticles have proven exceptional efficacy in detecting trace levels of cancer-associated biomolecules in physical fluids, facilitating non-invasive and fast analysis. This early detection is essential for enhancing prognosis and survival rates, because it lets in for timely intervention and treatment[5]. Revolutionizing Cancer Treatment Nanotechnology's effect on cancer remedy is equally transformative. One of the maximum massive improvements is the improvement of focused drug delivery structures. Traditional chemotherapy, while powerful, regularly consequences in intense aspect effects due to its non-particular nature, affecting each cancerous and healthy cell. Nanoparticles may be designed to supply chemotherapeutic sellers without delay to tumor cells, minimizing harm to healthy tissue and lowering aspect consequences[6]. Moreover, the particular houses of nanoparticles, which include their size, surface place, and functionalization capacity, allow for the controlled release of therapeutic retailers. This guarantees that the drug attention remains in the therapeutic window for an extended period, enhancing its efficacy and decreasing the frequency of administration[7]. Emerging Therapies and Innovations Recent research has established the potential of nanotechnology in developing novel cancer healing procedures. For example, nano-enzymes have shown promise in improving the effectiveness of radiotherapy via growing the sensitivity of tumor cells to radiation. Additionally, nanotechnology is facilitating the improvement of immunotherapies, wherein nanoparticles are used to modulate the immune gadget's response to most cancers cells, improving the body's herbal potential to fight most cancers[8].Furthermore, the combination of nanotechnology with different rising fields, such as artificial intelligence and personalised medication, is paving the way for the next technology of most cancers’ treatments. AI algorithms can analyse substantial datasets to identify patterns and expect responses to nanotechnology-based totally cures, enabling customized treatment plans tailored to character sufferers' genetic and molecular profiles[9]. Challenges and Future Directions While the ability of nanotechnology in most cancers care is sizeable, numerous demanding situations stay. Ensuring the safety and biocompatibility of nanoparticles is paramount, as their lengthy-time period outcomes on the human frame aren't but absolutely understood. Regulatory frameworks want to adapt to hold pace with those improvements, making sure that new nanotechnology-based treatments are thoroughly evaluated for safety and efficacy[9, 10].Future research needs to cognizance on overcoming those challenges and expanding the packages of nanotechnology in cancer care. Interdisciplinary collaborations among oncologists, nanotechnologists, and regulatory our bodies will be important in translating these innovations from the lab to the clinic[11, 12]. CONCLUSION Nanotechnology is certainly revolutionizing cancer analysis and remedy, presenting new hope for patients and remodelling the landscape of oncology. As we hold to discover and harness the capacity of this cutting-edge generation, the dream of greater powerful, less invasive, and customized most cancers care is turning into a reality. The ongoing advancements in nanotechnology promise to not simplest improve patient results but also pave the manner for a destiny in which most cancers are a doable, and possibly even curable, circumstance.
38
Zhao, Henu, Bryan Tysinger i Dana P. Goldman. "Valuing innovations in cancer treatment." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): e18176-e18176. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18176.
Pełny tekst źródłaStreszczenie:
e18176 Background: Established in 2004 by voter referendum, the California Institute for Regenerative Medicine funds stem-cell research aimed at reducing the burden of diseases, including cancer. Incidence for certain cancer has been reduced by half in the last decades. To better understand the social benefit of medical innovation, we estimate the potential value of interventions to reduce the incidence of selected cancers. Methods: We use the Future Elderly Model (FEM) to simulate scenarios calculating the national and California disease burden of breast, colorectal, lung, and prostate cancer and the societal value of reducing incidence of these cancers by 10% and 50%, respectively. FEM is a well-validated microsimulation model of Americans aged 51 and older that projects future health and economic outcomes for individuals. Starting with a nationally representative sample from the Health and Retirement Study, we estimate two-year transitions between chronic diseases, functional status, and economic outcomes. We predict EQ-5D scores and quality-adjusted life-years (QALY) based on the outcomes and models using Medical Expenditure Panel Survey data. We then aggregate individual results to generate outcomes at the societal level. Results: Social values are measured by QALY, with each unit valued at $150,000. Yearly discount rate for future QALY is 3%. Estimated gains in aggregate social value from 2018 to 2050 are presented below. For the selected cancers, the disease burden of the selected cancers through 2050 ranges from $1.3 trillion to $3 trillion for the U. S. population >50. QALY gains from a 50% reduction in incidence are estimated at $0.5 trillion to $1.4 trillion, while gains from a 10% reduction are $110 billion to $252 billion. Conclusions: A small incidence reduction can result in large returns. There is a lot of potential for innovation in cancer. [Table: see text]
39
Helman, Lee J. "Cancer Treatment." Journal of Pediatric Hematology/Oncology 23, nr 7 (październik 2001): 474. http://dx.doi.org/10.1097/00043426-200110000-00019.
Pełny tekst źródła
40
Matesich, Sister Mary Andrew, i Charles L. Shapiro. "Second cancers after breast cancer treatment". Seminars in Oncology 30, nr 6 (grudzień 2003): 740–48. http://dx.doi.org/10.1053/j.seminoncol.2003.08.022.
Pełny tekst źródła
41
Capelo Medina, E., J. Muñoz García, J. Quirós Rivero, M. Ropero Carmona, Y. Ríos Kavadoy, A. Corbacho Campos, A. Torres García i J. Cabrera Rodríguez. "Second cancers after breast cancer treatment". Reports of Practical Oncology & Radiotherapy 18 (czerwiec 2013): S183. http://dx.doi.org/10.1016/j.rpor.2013.03.112.
Pełny tekst źródła
42
Townsley, Carol A., Shari Moura, Barbara Fitzgerald, Gillian Hawker, Jane Mosley, Cris Barrett, Catharine Fox i Malcolm J. Moore. "An innovative approach to post-treatment cancer care: The After Cancer Treatment Transition Clinic (ACTT)." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): e19522-e19522. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e19522.
Pełny tekst źródłaStreszczenie:
e19522 Background: Improvements in early detection and cancer therapy have led to better survival rates. Integration of cancer survivorship initiatives as part of cancer care is gaining momentum. However, post cancer treatment follow up care may not be best met in acute cancer clinics. Visits to a large urban cancer centre in Canada have increased by 30% in the past 5 years. These increased volumes have lead to prolongation of patient wait times and increased stress for health care providers. This cancer centre is undergoing a transformative change that focuses on improving the patient cancer care experience. Methods: The development of the ACTT clinic has been a partnered initiative between two academic healthcare centres: an urban cancer centre and a community ambulatory hospital with a focus in chronic disease management. It is being managed by an advanced practice nurse and a GP Oncologist. The ACTT clinic delivers high quality, safe specialized physician and advanced nursing patient care, with engagement of patients/families, oncologists and primary care. The target population is patients who have completed cancer therapy, are well and are at moderate to low risk for cancer recurrence. The initial phase of the project involved transitioning patients with Testes, Melanoma, Breast and Colorectal cancers. Each cancer site group identifies the appropriate processes for clinic functioning at the ACTT, and if required, for appropriate linkages back to acute cancer care and primary care. Results: Over 1,000 patients have been transitioned to ACTT since April 2010 with 10-20 additional patients referred weekly. Essential components of the model include: standard surveillance protocols for recurrence or secondary cancers, management of long term and late effects of cancer treatment, monitoring for distress and health promotion. Standard reporting includes patient assessment and a defined plan of care communicated to their oncologist and primary care. Patient experience evaluation of the program is ongoing. Conclusions: The ACTT clinic initiative has been successful in developing a novel clinic model and has successfully transitioned over 1,000 patients from an acute care cancer clinic.
43
Moutaouakkil, Youssef, Hicham Fettah, Sara Rharrit, Sanaa Lhajoui, Jamal Elmssaouri, Ahmed Bennana i Sanaa Makram. "Immunotherapy in the treatment of cancer". Batna Journal of Medical Sciences (BJMS) 2, nr 2 (30.12.2012): 147–52. http://dx.doi.org/10.48087/bjmsra.2015.2210.
Pełny tekst źródłaStreszczenie:
L'immunothérapie est un traitement qui consiste à administrer des substances qui vont stimuler les défenses immunitaires de l'organisme afin de lutter contre différentes maladies, en particulier certains cancer hématologiques (autrement dit, du sang), les maladies dégénératives et les maladies de système. Par extension, l'immunothérapie désigne également toute thérapie utilisant des protéines produites par les cellules du système immunitaire, en particulier les immunoglobulines, sans que l'objectif de cette thérapie soit nécessairement la stimulation de l'immunité. Les premiers essais d'immunothérapie remontent aux années 1970 et utilisaient des anticorps polyclonaux. Actuellement différentes molécules sont utilisées, en premier lieu les immunoglobulines monoclonales, les interférons et les interleukines. On distingue deux types d'immunothérapies : l'immunothérapie locale dont les applications sont peu fréquentes et l'immunothérapie générale beaucoup plus fréquente.
44
Bravery, Benjamin, Siobhan Loughnan i Michael Murphy. "Depression treatment research in people with cancer does not reflect cancer prevalence: findings from a systematic review". Evidence Based Mental Health 23, nr 4 (11.08.2020): 155–60. http://dx.doi.org/10.1136/ebmental-2020-300145.
Pełny tekst źródłaStreszczenie:
BackgroundOne in six people with cancer will develop depression at some point in their care. Untreated depression affects quality of life, cancer care satisfaction and healthcare expenditure. Treatments for this vulnerable heterogenous population should be evidence based and specific. A common sentiment is that psychiatric research does not reflect the prevalence of patients with cancer and comorbid depression and is biased towards certain cancers, but this has not been empirically shown.Study selection and analysisA systematic review of studies on psychological and pharmacological treatments for depression in people with cancer was conducted. Of 4621 papers identified from a search of PubMed and PsycINFO up to 27 June 2020, 84 met inclusion criteria (eg, adults with cancer; depression diagnosis; treatment study) and comprised 6048 participants with depression with cancer.FindingsCancer types are not proportionally represented in depression research in accordance with their incidence. Breast cancer is over-represented (relative frequency in research 49.3%, but 11.7% of global cancer). Cancers of the head and neck and bone and soft tissue were close to parity. All other cancers are under-represented. Representativeness varied 40-fold across different cancers.ConclusionsThe evidence base for depression treatments is dominated by a single cancer. Given heterogeneity in cancer populations (eg, stage of illness; psychological impact; cancer treatments), it is possible that depression treatments may not have the same benefits and harms across all cancers, impeding the ability to offer people with different cancers the best depression treatment. While the dominant opinion within this research field is that a cancer bias exists, this is the first study to demonstrate as such.
45
Kim, Jin Won. "Gastrointestinal cancer treatment with immune checkpoint inhibitors". Journal of the Korean Medical Association 64, nr 5 (10.05.2021): 342–48. http://dx.doi.org/10.5124/jkma.2021.64.5.342.
Pełny tekst źródłaStreszczenie:
Immuno-oncological treatment approaches, particularly with the use of immune checkpoint inhibitors such as antiprogrammed death 1 (PD-1)/programmed death ligand 1 antibody or anti-cytotoxic T-lymphocyte associated protein 4 antibody, have become the standard treatment for gastrointestinal cancers. However, gastrointestinal cancers show an overall modest tumor response to immune checkpoint inhibitors. Nevertheless, subgroups such as tumors that are DNA mismatch repair-deficient or have high microsatellite instability particularly benefit from immune checkpoint inhibitors. Even in the first-line setting for colorectal cancer, the clinical efficacy of pembrolizumab, an anti–PD-1 antibody, was superior to that of chemotherapy. Recently, a combination of atezolizumab, an anti-programmed death ligand 1 antibody, and bevacizumab was approved as the first-line treatment for hepatocellular carcinoma, and was reported as superior to sorafenib. Nivolumab, an anti–PD-1 antibody that is added to chemotherapy as the first-line treatment for gastric cancer, resulted in longer survival compared with chemotherapy alone. Further studies are ongoing to investigate additional immune checkpoint inhibitors for other gastrointestinal cancers. This review aims to provide an overview of the results of clinical trials for immune checkpoint inhibitors in gastrointestinal cancers, including colorectal cancer, gastric cancer, hepatocellular carcinoma, pancreatic cancer, and biliary tract cancer.
46
Nam, Hye Jin. "Autophagy Modulators in Cancer: Focus on Cancer Treatment". Life 11, nr 8 (17.08.2021): 839. http://dx.doi.org/10.3390/life11080839.
Pełny tekst źródłaStreszczenie:
Uncontrolled autophagy has been associated with the development and progression of various cancers that are resistant to cancer therapy. Therefore, many efforts to modulate uncontrolled autophagy as a cancer treatment have been attempted, from basic science to clinical trials. However, it remains difficult to equally apply autophagy modulators to cancer therapy because autophagy is a double-edged sword in cancer: it can be tumor-suppressive or tumor-protective. Therefore, the precise mechanisms of autophagy modulators and their varied responsiveness to each cancer type should be addressed in detail. This study will describe the precise mechanisms of developing various autophagy modulators, their current therapeutic applications and future perspectives.
47
Cheng, Shih-Hsuan, Hsin-Ying Clair Chiou, Jiunn-Wei Wang i Ming-Hong Lin. "Reciprocal Regulation of Cancer-Associated Fibroblasts and Tumor Microenvironment in Gastrointestinal Cancer: Implications for Cancer Dormancy". Cancers 15, nr 9 (27.04.2023): 2513. http://dx.doi.org/10.3390/cancers15092513.
Pełny tekst źródłaStreszczenie:
Gastrointestinal (GI) cancers remain a major cause of cancer-related deaths worldwide. Despite the progress made in current treatments, patients with GI cancers still have high recurrence rates after initial treatment. Cancer dormancy, which involves the entry and escape of cancer cells from dormancy, is linked to treatment resistance, metastasis, and disease relapse. Recently, the role of the tumor microenvironment (TME) in disease progression and treatment has received increasing attention. The crosstalk between cancer-associated fibroblasts (CAF)-secreted cytokines/chemokines and other TME components, for example, extracellular matrix remodeling and immunomodulatory functions, play crucial roles in tumorigenesis. While there is limited direct evidence of a relationship between CAFs and cancer cell dormancy, this review explores the potential of CAF-secreted cytokines/chemokines to either promote cancer cell dormancy or awaken dormant cancer cells under different conditions, and the therapeutic strategies that may be applicable. By understanding the interactions between cytokines/chemokines released by CAFs and the TME, and their impact on the entry/escape of cancer dormancy, researchers may develop new strategies to reduce the risk of therapeutic relapse in patients with GI cancers.
48
Ogata, Takashi, Yota Shimoda, Kazuki Kano, Keisuke Koumori, Hayato Watanabe, Hirohito Fujikawa, Takanobu Yamada i Takashi Oshima. "Screening and treatment strategy for double cancer for esophageal cancer surgery patients." Journal of Clinical Oncology 38, nr 4_suppl (1.02.2020): 336. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.336.
Pełny tekst źródłaStreszczenie:
336 Background: Esophageal cancer treatment, especially esophagectomy, is highly invasive, so treatment strategies are considered in view of existing double cancers. On the other hand, in Japan, 90% of esophageal cancers are squamous cell carcinoma, and it is known that there are a large proportion of head and neck cancers for double cancers as field cancerization. Methods: The aim of this study is to investigate the types of double cancer, simultaneous/metachronous, and the frequency and treatment policy of head and neck cancer as a particularly high coexistence rate for esophageal cancer surgery patient. The subjects were 304 patients who underwent esophagectomy performed from April 2010 to December 2017. All patients were examined with high-definition endoscopy with NBI by certificated endoscopist at the first visit as a search for simultaneous double cancer from the pharynx to the stomach. And after esophagectomy, endoscopy was also performed to check for metachronous double cancers in the remaining esophagus, gastric tube, and pharynx at least every 2 years. Results: The number of double cancer cases was found in 94 cases (30.9%), and the total number of double cancer cases was 122. Head and neck cancer(33 cases), stomach cancer(16 cases), and colon cancer(12 cases) were observed as the main course of double cancers. In double cancer cases, 47cases(50.0%) were metachronous, 35cases(37.2%) were simultaneous, and 12cases(12.8%) were both synchronous. The most common double cancer was head and neck cancer(33 cases:35.1%), and 23 cases were simultaneous, 10 cases were metachronous. As treatment strategy for head and neck cancer, endoscopic laryngo-pharyngo surgery(ELPS) were 19 cases. 10 cases(52.7%) were synchronous cancers, and 9 cases (47.3%) were metachronous cancers which were detected during follow-up after esophagectomy. Conclusions: Head and neck cancer associated with esophageal cancer surgery is the most common type of double cancer, and 1/3 of ELPS cases have been detected by follow-up endoscopy after esophagectomy, so endoscopic surveillance was also considered important.
49
Panzone, John, Timothy Byler, Gennady Bratslavsky i Hanan Goldberg. "Applications of Focused Ultrasound in the Treatment of Genitourinary Cancers". Cancers 14, nr 6 (17.03.2022): 1536. http://dx.doi.org/10.3390/cancers14061536.
Pełny tekst źródłaStreszczenie:
Traditional cancer treatments have been associated with substantial morbidity for patients. Focused ultrasound offers a novel modality for the treatment of various forms of cancer which may offer effective oncological control and low morbidity. We performed a review of PubMed articles assessing the current applications of focused ultrasound in the treatment of genitourinary cancers, including prostate, kidney, bladder, penile, and testicular cancer. Current research indicates that high-intensity focused ultrasound (HIFU) focal therapy offers effective short-term oncologic control of localized prostate and kidney cancer with lower associated morbidity than radical surgery. In addition, studies in mice have demonstrated that focused ultrasound treatment increases the accuracy of chemotherapeutic drug delivery, the efficacy of drug uptake, and cytotoxic effects within targeted cancer cells. Ultrasound-based therapy shows promise for the treatment of genitourinary cancers. Further research should continue to investigate focused ultrasound as an alternative cancer treatment option or as a complement to increase the efficacy of conventional treatments such as chemotherapy and radiotherapy.
50
Park, Seong Yong. "Surgical treatment of esophageal cancer". Journal of the Korean Medical Association 67, nr 2 (10.02.2024): 124–31. http://dx.doi.org/10.5124/jkma.2024.67.2.124.
Pełny tekst źródłaStreszczenie:
Background: Esophageal cancer was the seventh most common cancer worldwide in 2020 and the sixth leading cause of cancer-related deaths (544,000 deaths annually), accounting for one-eighteenth of all cancer-related deaths. In Korea, esophageal cancer accounted for 1.0% of all cancer cases, with 2,483 cases diagnosed in 2017, making it the fifteenth most common cancer and the eleventh most common cause of cancer-related deaths.Current Concepts: Esophageal squamous cell cancer (ESCC) is the most prevalent pathology (91.2%) in Korea, typically affecting the upper and middle esophagus. The common causes of ESCC are smoking, drinking, and hot beverages. ESCC lesions confined to the mucosa, such as cTis and cT1a, can be treated with endoscopic resection, but lesions invading the submucosa require esophagectomy. Patients with locally advanced ESCC with lymph node metastasis require neoadjuvant therapy followed by esophagectomy and reconstruction. Esophagectomy is associated with mortality and morbidity rates of 3% and 50%, respectively.Discussion and Conclusion: ESCC is associated with a poorer prognosis compared to those associated with other cancers, and the high mortality and morbidity rates associated with esophagectomy often lead to hesitation toward aggressive treatments. However, recent advances in chemotherapy, radiation therapy, and surgery can offer hope for a cure. Minimally invasive esophagectomy may reduce the rate of fatal complications. The shift from traditional platinum-based chemotherapy to immune checkpoint inhibitors also suggests promise for the treatment outcomes of ESCC.